Last edition
News about "Argo Biopharma"
Argo Biopharma Doses First Patient in Phase 1 Trial of siRNA Drug BW-50218
Argo Biopharma doses first patient in Phase 1 trial of BW-50218, an siRNA therapeutic from its RADS platform designed for potent, durable gene silencing with targeted hepatic delivery and improved safety.
Argo Biopharma | 29/04/2026 | By News Bureau
Argo Biopharma's siRNA Therapy BW-20805 Gets FDA Fast Track for HAE
Argo Biopharma has received FDA Fast Track designation for BW-20805, with an ongoing global phase-II study in adult HAE patients and primary completion expected in the second half of 2026.
Argo Biopharma | 17/03/2026 | By News Bureau
Argo Biopharma and Novartis Partner on Novel Cardiovascular Therapies
Argo to receive $160 million upfront as Novartis licenses pipeline assets, explores ANGPTL3 in dyslipidemia, and secures options for future siRNA candidates.
Argo Biopharma | 05/09/2025 | By Dineshwori | 356
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy